Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech reports preliminary blinded CRc rate of 37% in MIRACLE trial for R/R AML with no cardiotoxicity observed (Items: 7.01 of this Current Report on Form 8-K, including Exhibit 99)
Tickers: $MBRX
More Regulatory news
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing
- Neonode Inc. - 10-Q Filing
- Virtuix Holdings Inc. - 8-K Filing
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing